National Institute Of Diabetes And Digestive And Kidney Diseases (niddk)

This study is testing whether giving two immune-suppressing drugs (rituximab-pvvr followed by abatacept) is better than one drug alone for people recently diagnosed with type 1 diabetes. The main goal is to see if the combination helps the body preserve its own ability to make in…

This study is testing two experimental drugs, abrocitinib and ritlecitinib, to see if they can help preserve the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. The trial involves 78 participants aged 12-35 who were diagnosed within the…

This study provides continued access to the drug metreleptin for people with partial lipodystrophy, a rare condition that causes severe diabetes and high blood fats. It is for patients who have already benefited from the drug in past NIH studies but cannot get it through regular …

This study provides continued access to the drug metreleptin for people with a rare condition called generalized lipodystrophy who have previously received it through NIH research and cannot get it through normal channels in their home country. It aims to monitor the long-term sa…

This study follows people who have been cured of chronic hepatitis C for up to 10 years to understand their long-term health. Researchers want to see if cured patients still develop liver complications, cancer, or other health problems over time. The study involves regular check-…

This study follows American Indians with type 2 diabetes to understand the long-term effects of a previous kidney treatment trial. Researchers are observing how kidney disease progresses over many years through regular tests, scans, and optional biopsies. No new treatment is prov…

This study aims to discover the specific genes and biological pathways that influence a person's risk of developing type 2 diabetes and related health problems like kidney and eye disease. Researchers will collect health information, blood samples, and genetic data from over 2,00…